 |
Wuhan Nutra Biotechnology Co., Ltd.ISRIB ,Cosmetic Peptide, Tideglusib ,Way316606,Nootropics |
    
   
|
|||
Contact Us
E-mail: catherine@nutrabiotechchem.com
Vorinostat
Product Description:
Product Name: Vorinostat
Synonyms: Octanediamide, N1-hydroxy-N8-phenyl-;SAHA=N-Hydroxy-N'-phenyloctanediamide;SAHA, N-Hydroxy-Nphenyloctanediamide, Zolinza;Zolinza (See Suberoylanilide Hydroxamic Acid);Vorinostat;N-Hyrdroxy-N'-phenyloctanediamide;Suberanilohydroxamic acid;Suberoylanilide hydroxamic acid
CAS: 149647-78-9
MF: C14H20N2O3
MW: 264.32
Vorinostat (rINN)also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Vorinostat is marketed under the name Zolinza (zo-linz-ah) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks
Synonyms: Octanediamide, N1-hydroxy-N8-phenyl-;SAHA=N-Hydroxy-N'-phenyloctanediamide;SAHA, N-Hydroxy-Nphenyloctanediamide, Zolinza;Zolinza (See Suberoylanilide Hydroxamic Acid);Vorinostat;N-Hyrdroxy-N'-phenyloctanediamide;Suberanilohydroxamic acid;Suberoylanilide hydroxamic acid
CAS: 149647-78-9
MF: C14H20N2O3
MW: 264.32
Vorinostat (rINN)also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Vorinostat is marketed under the name Zolinza (zo-linz-ah) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks
Links:
Copyright © Wuhan Nutra Biotechnology Co., Ltd. All right reserved
